A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme
David K Lau, Miles C Andrews, Natalie Turner, Arun A Azad, Ian D Davis, Jonathan S Cebon
Melanoma Research | LIPPINCOTT WILLIAMS & WILKINS | Published : 2014
We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion into clinical trials were offered treatment with dabrafenib through a named patient programme. Routine efficacy and toxicity data were collected throughout treatment and studied retrospectively. The endpoints were progression-free survival (PFS), overall survival and best overall response. Thirty-one patients commenced dabrafenib therapy including six individuals who had progress..View full abstract
Awarded by Australian National Health and Medical Research Council (NHMRC)
Awarded by NHMRC Medical Postgraduate Research Scholarship (NHMRC)
The authors thank participating patients and families; Anna Lucas and Jim Siderov for their expert assistance in managing and dispensing patient supplies of dabrafenib; Joanne Hawking for her expertise in the melanoma clinic; Dr Katrina Vanin and the staff at GSK Australia. JC is supported in part by grants from the Melanoma Research Agency (MRA), the Australian National Health and Medical Research Council (NHMRC, Project #1007381) and Victorian State Government Operational Infrastructure Support Program. MA is supported by an NHMRC Medical Postgraduate Research Scholarship (NHMRC #1055456).